[Webinar] Listing of Biotech Companies

[Webinar] Listing of Biotech Companies

New Seminar

Overview

On 30 April 2018, HKEX launched the new Listing Rules that aimed at broadening Hong Kong’s listing regime to attract the listings of pre-revenue biotech companies, including companies engaged in pharmaceuticals biologics and medical devices.

In this webinar, the speakers will give an overview of the biotech IPO fundraisings on HKEx, the listing requirements, valuation of biotech companies and the key accounting and tax matters of biotech companies which are of critical importance for a successful listing in Hong Kong.

Objective

By the end of this webinar, participants will be able to:

- Know the listing requirements, valuation approaches for biotech companies and the key focus areas which are crucial for a successful listing in Hong Kong.

Content

1. Overview of the biotech IPO fundraisings on HKEX
2. Listing requirements
3. Key focus areas which are of critical importance for a successful listing in Hong Kong
4. Valuation of biotech companies

Who should attend

- Sponsors and IPO practitioners
- Corporate finance advisers
- Executives, senior management and company secretaries of biotech companies preparing for listing
- Asset and fund managers
- Valuers
- Investors who are interested in biotech companies

Speaker/Course Instructor

Edmond CHAN
Edmond has extensive IPO and capital market engagement experience. He is currently a member of the Listing Committee of the Hong Kong Stock Exchange.

His clientele is diverse and includes a wide range of Hong Kong, mainland China and international based clients covering different industries. Edmond is specialised in IPO and capital market projects. He has extensive experience in financial reporting, group reorganization, and other related listing issues. He has assisted many clients, including a number of biotech companies under Chapter 18A, in listing successfully on the stock exchanges in Hong Kong, mainland China, Singapore and the United States over the years.
Amelia YAU
Amelia has more than 29 years of experience in public accounting and has ample knowledge and experience in serving large complex multinational conglomerates and organisations in the public sector. She has been involved in capital market transactions including corporate restructuring, privatization and initial public offering in China and Hong Kong. Amelia has extensive knowledge and experience in resolving complex accounting issues that a biotech company normally encountered. In addition, she has taken the role of Market Leader of PwC Southern China Biotech Focus Group, to provide comprehensive services to biotech companies.

Amelia is currently a fellow member of Hong Kong Institute of Certified Public Accountants (HKICPA) and the Institute of Chartered Accountants in England & Wales (ICAEW).
Spencer TSE
Spencer has more than 28 years of experience in advising on valuation and transactions to clients for merger and acquisition, corporate strategic planning and restructuring, litigation, financial reporting and tax reporting purposes. Clients that Spencer served included quasi-government bodies, local and international corporations. Spencer has extensive experience in various industries and focusing on medical and healthcare sector. He had advised clients on various start-up biotech companies, pharmaceutical companies, medical equipment and distributors, etc.

Spencer is a member of the HK Business Valuation Quality Initiative Task Force set up by regulators, professional bodies and business chambers in HK.
Rebecca WONG
Rebecca is a China tax partner of PwC China. She has been working in Hong Kong and Southern China over 20 years. She is knowledgeable in advising clients on cross-border tax and business matters.

Rebecca is familiar with China tax, foreign exchange and business regulatory issues and has extensive experiences in providing practical solutions to deal with dynamic business issues. Her expertise includes advices on tax effective structure; M&A tax due diligence and post-deal integration; pre IPO restructuring and employee stock incentive advice; application of tax incentives; tax disputes resolution; repatriation of funds; etc. Her clients include a number of multinational and domestic companies in TMT, pharmaceutical, manufacturing , retail, education and private equity industries.

Rebecca is a guest speaker in many public events and has participated in various government policy draft discussions. She is the China tax sub-committee member of HKICPA, South China Founding Committee Member of CPA Australia; taxation sub-committee member of ACCA Hongkong.

Details

Code
TSURE20001201
Date & Time
Wednesday, 28 Oct 2020 (12:20PM - 1:20PM)
Venue
Virtual Platform
Language
English
Level
Intermediate
Hours
SFC:1.00, PWMA:1.00